Predictors of Virological Response to a Combination Therapy with Pegylated Interferon Plus Ribavirin Including Virus and Host Factors

Author(s): Namiki Izumi | Yasuhiro Asahina | Masayuki Kurosaki

Antiviral therapy in HCV-infected decompensated cirrhotics

Author(s): Danish Fazal | Koul Salman | Subhani Fazal | Rabbani Ahmed | Yasmin Saeeda

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin

Author(s): Roberto J Carvalho-Filho | Olav Dalgard

Targeted therapies in the management of renal cell carcinoma: role of bevacizumab

Author(s): Bernard Escudier | Jan Cosaert | Sangeeta Jethwa

Managing pediatric hepatitis C: current and emerging treatment options

Author(s): Wikrom Karnsakul | Mary Kay Alford | Kathleen B Schwarz

Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy

Author(s): Emara Mohamed | El-Gammal Nahla | Mohamed Lamiaa | Bahgat Maged

Hepatocellular carcinoma, with portal thrombus after viral eradication, disappeared by 5-fluorouracil and interferon

Author(s): Tomofumi Miura, Nobuaki Suzuki, Junichiro Nakamura, Satoshi Yamada, Tsutomu Miura, Masahiko Yanagi, Hiroyuki Usuda, Iwao Emura, Toru Takahashi

New means to monitor the effect of glucocorticoid therapy in children

Author(s): Hanne Rintamäki, Harri M Salo, Outi Vaarala, Kaija-Leena Kolho

Microalbuminuria in hepatitis C-genotype 4: Effect of pegylated interferon and ribavirin

Author(s): Moutaz Derbala, Fatma M Shebl, Awad Rashid, Aliaa Amer, Abdulbari Bener

Sustained virologic response following HCV eradication in two brothers with X-linked agammaglobulinaemia

Author(s): Diarmaid D Houlihan, Eoin R Storan, John M Lee

Retinoic acid inducible gene I Activates innate antiviral response against human parainfluenza virus type 3

Author(s): Sabbah Ahmed | Bose Santanu

Infection with hepatitis C virus genotype 3 - Experience of a tertiary health care centre in south India

Recent Advances in the Management of Multiple Sclerosis

Author(s): Carlo Pozzilli | Luca Prosperini

The bevacizumab experience in advanced renal cell carcinoma

Author(s): Lauren C Harshman | Sandy Srinivas

Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa

Author(s): Wang Shaoyang | Huang Dedong | Sun Shunlai | Ma Weimin | Zhen Qin

An overview of treatment response rates to various anti-viral drugs in Pakistani Hepatitis B Virus infected patients

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

Author(s): Mosaburo Kainuma, Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Yuichi Tanabe, Takeaki Satoh, Toshihiro Maruyama, Makoto Nakamuta, Kazuhiro Kotoh, Koichi Azuma, Junya Shimono, Shinji Shimoda, Jun Hayashi, The Kyushu University Liver Disease Study Group

Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: A phase II study

Author(s): Annagiulia Gramenzi, Carmela Cursaro, Marzia Margotti, Clara Balsano, Alessandra Spaziani, Simona Anticoli, Elisabetta Loggi, Maddalena Salerno, Silvia Galli, Giuliano Furlini, Mauro Bernardi, Pietro Andreone

Hepatitis C virus and type 2 diabetes

Author(s): Francesco Negro, Mahnaz Alaei

Extended-therapy duration for chronic hepatitis C, genotype 1: The long and the short of it

Author(s): Brian L Pearlman

Treatment of chronic hepatitis B

Author(s): G. Montazeri | M. R. Ghadir | Rohban M | Estakhri A

Evasion of the Interferon-Mediated Antiviral Response by Filoviruses

Author(s): Washington B. Cárdenas

Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment

Author(s): Nuntra Suwantarat, Alan D. Tice, Thana Khawcharoenporn, Dominic C. Chow

Efficacy of triple therapy with interferon alpha-2b, ribavirin and amantadine in the treatment of naïve patients with chronic hepatitis C

Author(s): Hamid Kalantari | Fatemeh Kazemi | Mohammad Minakari

Current Management of Advanced and Metastatic Renal Cell Carcinoma

Author(s): M Hamad Ather | Nehal Masood | Tahmeena Siddiqui

Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy

Author(s): Al-Qahtani Ahmed | Kessie George | Cruz Damian | Al-Faleh Faleh | Al-Ahdal Mohammed

Flares on and off therapy during chronic HBV infection: Pathogenesis, significance and management

Author(s): Amarapurkar Deepak

A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899

Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial

Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma

Interferon-Alpha Induced and Ribavirin Induced Thyroid Dysfunction in Patients with Chronic Hepatitis C

Author(s): Amina Nadeem | Muhammad Mazhar Hussain | Muhammad Aslam | Tassawar Hussain

Beta-interferons in multiple sclerosis: A single center experience in India

Author(s): Gupta Salil | Varadarajulu R | Ganjoo R

Interferon alpha-2b in genital warts

Prediction of prognostic biomarkers for Interferon-based therapy to Hepatitis C Virus patients: a metaanalysis of the NS5A protein in subtypes 1a, 1b, and 3a

Author(s): ElHefnawi Mahmoud | Zada Suher | El-Azab Iman

Nutrigenomics Therapy of Hepatisis C Virus Induced-hepatosteatosis

Author(s): Liu Qing | Bengmark Stig | Qu Shen

Human immunodeficiency virus type I-specific CD8+ T cell subset abnormalities in chronic infection persist through effective antiretroviral therapy

Author(s): Pohling Julia | Zipperlen Katrin | Hollett Natasha | Gallant Maureen | Grant Michael

Reversion and conversion of Mycobacterium tuberculosis IFN-γ ELISpot results during anti-tuberculous treatment in HIV-infected children

Research Article JCST/Vol.2.1 016-025 (2010) doi:10.4172/1948-5956.1000018 Characterization of Treatment Response to Recombinant Interferon-a2b in Osteosarcoma Xenografts

Author(s): Christoph R Müller | Heidi M Namløs | Johan Bjerner | Ingrid HG Østensen | Gunnar Sæter

Characterization of Treatment Response to Recombinant Interferon-α2b in Osteosarcoma Xenografts

Author(s): Christoph R Müller | Heidi M Namløs | Johan Bjerner | Ingrid HG Østensen | Gunnar Saeter

Interferon-λ in HCV Infection and Therapy

Author(s): Nicole E. Pagliaccetti | Michael D. Robek

Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case

Author(s): Schildgen Verena | Ziegler Susanne | Tillmann Ramona | Schildgen Oliver

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?

Abnormal macrophage response to microbial stimulus in a 43-year-old man with a severe form of atherosclerosis: a case report

Activation of Multiple Molecular Mechanisms for Increasing Apoptosis in Human Glioblastoma T98G Xenograft

Author(s): Surajit Karmakar | Subhasree Roy Choudhury | Naren L. Banik | Swapan K. Ray

The effect of combined chemotherapy with or without potentiation with interferon alpha or tamoxifen for melanoma

Sequence variability at the internal ribosome entry site of the HCV genome in relation to therapy outcome

Immunotherapy and Therapeutic antibodies

Late onset of severe thrombocytopenia during interferon treatment for chronic hepatitis C infection: Case report

Author(s): Hajder Jelena | Stanisavljević Nataša | Marković Olivera | Marisavljević Dragomir

Efficacy of combined antiviral therapy with pegylated interferon α-2a and ribavirin for chronic hepatitis C infection in intravenous drug users

Treatment of chronic hepatitis C with pegylated-interferon

Author(s): Fabri Milotka J. | Božić Milena | Delić Dragan | Ješić Rada | Nožić Darko

Efficacy and safety of peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus infection

Author(s): Delić Dragan

Effects of interferons on hepatitis C virus infection

Author(s): Bojić Ivanko | Dokić Ljubiša | Minić Svetlana

The role of interferon in the treatment of acute hepatitis C

Author(s): Simonović-Babić Jasmina | Delić Dragan | Švirtlih Neda

Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial

Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C

USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS

Author(s): Paola Mancino | Katia Falasca | Claudio Ucciferri | Eligio Pizzigallo | Jacopo Vecchiet

A review on epidemiology, diagnosis and treatment of hepatitis D virus infection

Author(s): Eskandar Hajiani | Seyed Mohammad Alavi

Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection

Author(s): H Jafferbhoy | W Gashau | JF Dillon

Pegylated interferon 2a and 2b in combination with ribavirin for the treatment of chronic hepatitis C in HIV infected patients

Author(s): Ravinder Dhillon | Simona Rossi | Steven K Herrine

Review of consensus interferon in the treatment of chronic hepatitis C

Author(s): Th Witthöft

Management of chronic hepatitis C treatment failures: role of consensus interferon

Author(s): Stevan A Gonzalez | Emmet B Keeffe

Managing hepatitis C in liver transplant patients with recurrent infection

Author(s): Tim Zimmermann | Gerd Otto | Marcus Schuchmann

CHRONIC HEPATITIS C; RESPONSE TO INTERFERON AND RIBAVIRIN COMBINATION

Author(s): SHAUKAT ALI | SYED KHURRAM SHAHZAD

Prevalence and Clinical Relevance of Serum Autoantibodies in Patients with Chronic Hepatitis C

Cryoglobulinemia in elderly patients with HCV-related chronic hepatitis

Evaluation of signal transduction pathways after transient cutaneous adenoviral gene delivery

Mutations in the E2-PePHD region of hepatitis C virus genotype-3a and correlation with response to interferon and ribavirin combination therapy in Pakistani patients

New approaches in the diagnosis and treatment of latent tuberculosis infection

Author(s): Ahmad Suhail

Combination treatment in HBeAg-negative chronic hepatitis B

Author(s): Konstantinos Tziomalos

Safety of pegylated interferon and ribavirin therapy for chronic hepatitis C in patients with sickle cell anemia

Author(s): Hussain Issa

Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C

Author(s): Hiroaki Okushin, Kazuhiko Morii, Koichi Uesaka, Shiro Yuasa

Peginterferon and ribavirin treatment for hepatitis C virus infection

Author(s): Akihito Tsubota, Kiyotaka Fujise, Yoshihisa Namiki,Norio Tada

Hepatitis C Virus Genotypes: Clinical Relevance and Therapeutic Implications

Author(s): Chuan-Mo Lee | Chao-Hung Hung | Sheng-Nan Lu | Chi-Sin Changchien

Pegylated interferon α-2b up-regulates specific CD8+ T cells in patients with chronic hepatitis B

Author(s): Ji Chen, Yan Wang, Xue-Jie Wu, Jun Li, Feng-Qin Hou, Gui-Qiang Wang.

On-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formula

Author(s): Hidetsugu Saito, Hirotoshi Ebinuma, Keisuke Ojiro, Kanji Wakabayashi, Mika Inoue, Shinichiro Tada, Toshifumi Hibi

Serum immune-activation potency and response to anti-TNF-α therapy in Crohn's disease

Author(s): Hanne Rintamäki, Taina Sipponen, Harri M Salo, Outi Vaarala, Kaija-Leena Kolho

Treatment strategies for nodal and gastrointestinal follicular lymphoma: Current status and future development

Author(s): Takuya Watanabe

Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C

Author(s): Masayoshi Yada, Akihide Masumoto, Naoki Yamashita, Kenta Motomura, Toshimasa Koyanagi, Shigeru Sakamoto

Successful antiviral therapy is associated with a decrease of serum prohepcidin in chronic hepatitis C

Author(s): Jerzy Jaroszewicz, Magdalena Rogalska, Iwona Flisiak, Robert Flisiak

Alkaline phosphatase predicts relapse in chronic hepatitis C patients with end-of-treatment response

Author(s): Gerd Bodlaj, Rainer Hubmann, Karim Saleh, Tatjana Stojakovic, Georg Biesenbach, Jörg Berg

Hepatitis B virus infection and renal transplantation

Author(s): Ming-Chao Tsai, Yen-Ta Chen, Yu-Shu Chien, Te-Chuan Chen, Tsung-Hui Hu

Enhancement of antitumor vaccine in ablated hepatocellular carcinoma by high-intensity focused ultrasound

Author(s): Ying Zhang, Jian Deng, Jun Feng, Feng Wu

Precise prediction model and simplified scoring system for sustained combined response to interferon-α

Author(s): Qian-Guo Mao, Jin-Shui Pan, Kuang-Nan Fang, Ru-Mian Zhang, Qing-Yang Hong, Min-Ning Song, Jian-Ping Zhu, Wen-Qi Huang, Li-Min Chen, Mei-Zhu Hong

Interstitial Pneumonitis after Combination Therapy with Pegylated Interferon α-2b and Ribavirin for Chronic Hepatitis C

Author(s): Yung Che Chen | Sheng-Nan Lu | Meng-Chih Lin

Clinical relevance and public health significance of hepatitis B virus genomic variations

Author(s): Guang-Wen Cao

Positional effect of mutations in 5'UTR of hepatitis C virus 4a on patients' response to therapy

Author(s): Mostafa K El Awady, Hassan M Azzazy, Ahmed M Fahmy, Sherif M Shawky, Noha G Badreldin, Samar S Yossef, Moataza H Omran, Abdel Rahman N Zekri, Said A Goueli

Hepatitis C comorbidities affecting the course and response to therapy

Author(s): Abdel-Rahman El-Zayadi

APRI as a predictor of early viral response in chronic hepatitis C patients

Author(s): José A Mata-Marín, José L Fuentes-Allen, Jesús Gaytán-Martínez, Bulmaro Manjarrez-Téllez, Alberto Chaparro-Sánchez, Carla I Arroyo-Anduiza

Concomitant Nevirapine Therapy is Associated with Higher Efficacy of Pegylated Interferon Plus Ribavirin among HIV/ Hepatitis C Virus-Coinfected Patients

Author(s): Juan A. Pineda

Overwhelming postsplenectomy infection syndrome in adults - A clinically preventable disease

Author(s): Takehiro Okabayashi, Kazuhiro Hanazaki

Efficacy and safety of pegylated-interferon -2a in hemodialysis patients with chronic hepatitis C

Author(s): Celal Ayaz, Mustafa Kemal Celen, Ugur Nedim Yuce, Mehmet Faruk Geyik

Influence of quasispecies on virological responses and disease severity in patients with chronic hepatitis C

Author(s): Deepak Kumar, Abdul Malik, Mohammad Asim, Anita Chakravarti, Rakha H Das, Premashis Kar

Effects of antiviral agents and HBV genotypes on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients

Author(s): Hai-Ying Lu, Li-Wei Zhuang, Yan-Yan Yu, Chong-Wen Si, Jun Li, Jian-Jun Zhang, Zheng Zeng, Xin-Yue Chen, Zhong-Hou Han, Yong Chen

Molecular mechanisms of insulin resistance in chronic hepatitis C

Author(s): Mark W Douglas, Jacob George

Sustained virological response based on rapid virological response in genotype-3 chronic hepatitis C treated with standard interferon in the Pakistani population

Author(s): Bader Faiyaz Zuberi, Faisal Faiyaz Zuberi, Sajjad Ali Memon, Muhammad Hafeez Qureshi, Sheikh Zafar Ali, Salahuddin Afsar

Management of hepatitis C virus infection in HIV/HCV co-infected patients: Clinical review

Author(s): Ashwani K Singal, Bhupinderjit S Anand

Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan

Author(s): Takayuki Kogure, Yoshiyuki Ueno, Koji Fukushima, Futoshi Nagasaki, Yasuteru Kondo, Jun Inoue, Yasunori Matsuda, Eiji Kakazu, Takeshi Yamamoto, Hiroyoshi Onodera, Yutaka Miyazaki, Hiromasa Okamoto, Takehiro Akahane, Tomoo Kobayashi, Yutaka Mano, Takao Iwasaki, Motoyasu Ishii, Tooru Shimosegawa

Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?

Author(s): Ijaz S Jamall, Shafaq Yusuf, Maimoona Azhar, Selene Jamall

Hepatic steatosis: A benign disease or a silent killer

Author(s): Abdel-Rahman El-Zayadi

The sustained virologic response of nonresponder hepatitis C virus patients with retreatment

Author(s): Akhan Sila | Gurel Erdem | Sayan Murat

Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming

Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy

Type I interferon receptor in peripheral blood mononuclear cells may predict response to intra-arterial 5-fluorouracil + interferon therapy for advanced hepatocellular carcinoma

Extraskeletal effects of vitamin D

Author(s): Maurizio Rossini

Hepatocellular carcinoma-specific immunotherapy with synthesized α1,3- galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells